Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches
Carmine D’Amico, Manlio Fusciello, Firas Hamdan, Federica D’Alessio, Paolo Bottega, Milda Saklauskaite, Salvatore Russo, Justin Cerioni, Khalil Elbadri, Marianna Kemell, Jouni Hirvonen, Vincenzo Cerullo, Hélder A. Santos
Abstract
leading to complete tumor rejection when mice were pre-vaccinated. A rise in the cDC1 population in the lymph nodes of the MN treated mice led to an increase in the effector memory T cells in the body. Thus, the results of this study demonstrate that the combination of MN technology with PeptiCRAd may provide a safer, more tolerable, and efficient approach to cancer immunotherapy, potentially translatable to other therapeutic applications.
Topics & Concepts
TransdermalMaterials scienceBiomedical engineeringMedicinePharmacologyAdvancements in Transdermal Drug DeliveryToxin Mechanisms and ImmunotoxinsImmunotherapy and Immune Responses